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Abstract  
Hepatocellular carcinoma (HCC) is the most often primary cancer of the liver and is one if the 
leading cause of cancer-related death worldwide. The incidence of HCC has geographic distribution 
with the highest levels in countries with developing economies. Patients with hepatocellular 
carcinoma have poor prognosis despite the achievements in surgery techniques and other 
therapeutic procedures and it is a reason why continuous attention should be paid to this issue. 
This article provides an overview of this disease based on an extensive review of relevant literature. 
The article summarizes the current risk factors, diagnosis, staging and the management of HCC. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Liver cancer is the fifth most common cancer 
in men and the seventh in women [1]. World-wide 
incidence is between 250,000 and 1,000,000 new 
cases per year with a male-female ratio of about 4 or 
5:1 [2]. Hepatocellular carcinoma (HCC) is the most 
often primary cancer of the liver, accounting from 85% 
till 90% of all primary liver cancers [3]. Its occurrence 
reaches a peak at approximately 70 years of age with 
a rarely occurrence before the age of 40 years. Major 
risk factors for HCC include chronic alcohol 
consumption, hepatitis B, hepatitis C and non-
alcoholic fatty liver disease [3]. Other, less common 
causes are Wilson’s disease, hereditary 
hemochromatosis, alpha1-antitrypsin deficiency, 
primary biliary cirrhosis and autoimmune hepatitis [4, 
5]. The incidence of HCC in different regions of the 
world varies due to the incidence of the risk factors. 
Such countries are China, sub-Saharan Africa, Hong 
Kong and Taiwan with more than 15 cases per 
100,000 populations per year [6]. Any agent leading to 
chronic hepatic injury and eventually cirrhosis has 
been associated with HCC. Although multiple etiologic 
factors are responsible for HCC, it has been made a 
significant progress in these past years in the 
understanding of the molecular mechanisms and the 
pathogenesis of this disease. This article provides an 
overview of this disease based on our extensive 
review of relevant literature. We will summarize the 
current risk factors, diagnosis, staging and the 
management of HCC. 
Global variation of the incidence of HCC is in 
relation with the complex etiology of the neoplasm and 
the literature data depends on the evaluated region 
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and population, time in which the studies are done or 
the used methodologies.  
 
Figure 1: Estimated Liver Cancer Incidence Worldwide in 2012: 
Men (http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp) 
 
Relevant information can be provided by 
GLOBALCAN database maintained by the 
International Agency for Research on Cancer (Figure 
1, 2) [7, 8]. 
 
 
Figure 2: Estimated Liver Cancer Incidence Worldwide in 2012: 
Women (http://globocan.iarc.fr/old/FactSheets/cancers/liver-
new.asp) 
 
 
Risk factors 
 
Almost 50% of all cases of HCC are 
associated with HBV infection and 25% are 
associated with HCV [9]. HBV is double-stranded 
DNA-containing virus that is able to integrate its DNA 
into the hepatic cells, act as a mutagenic agent and 
cause secondary chromosomal rearrangement and 
increasing genomic instability [10]. This is the reason 
why the risk of HCC development is 100-fold higher 
for patients who are infected with HBV in comparison 
with those who are not infected [11]. 
Major cause of HCC in Europe, Japan, Latin 
America and the United States is cirrhosis caused by 
hepatitis C virus infection and the annual incidence 
ranges from 2% to 8% [9, 10]. Generally HCV-infected 
patients have 17 fold higher risk of developing HCC 
than uninfected [11-13]. HCV is an RNA-containing 
virus, unable to integrate into the host genome and 
therefore causes HCC by various indirect 
mechanisms such as alterations in apoptotic 
pathways and tumor formation [5, 14]. 
Obesity and diabetes mellitus have been 
correlated with increased risk of HCC [15, 16]. These 
patients have twice higher chance of developing HCC 
compared to those who are not obese and do not 
have diabetes [17]. Alcohol is another important risk 
factor for developing HCC with increasing as levels of 
alcohol intake rise [16]. Chronic consumption of 
alcohol from 40 to 60 grams of alcohol on a daily 
bases are highly associated with HCC [18]. Aflatoxin 
is a mycotoxin produced by Aspergillus flavus and 
related fungus that contaminates stored foods such as 
rice, corn, soybeans, and peanuts. In some regions of 
the world, especially in Asia and Africa, it is major risk 
factors of HCC [19]. Chronic exposure to aflatoxin is 
highly associated with HCC due to damaging the DNA 
of hepatic cells and causing mutation of the p53 tumor 
suppressor gene [20]. Mutations of other genes and 
chromosome aberrations are described in HCC also. 
Point mutation of the c-KRAS gene and co-
amplification of the cyclin D1 gene are rare and are 
detected in 3% and 11% of HCCs respectively. 
Mutations of beta-catenin gene are detected in 26-
41% of HCCs. Frequent allelic losses are reported at 
loci 1p, 4q, 5q, 8p, 11p, 13q, 16p, 16q and 17p and 
loss of heterozygosity (LOH) is reported on 
chromosome 16. Reduction of expression of 
p21WAF/CIP1 (universal CDK inhibitor), P16 protein 
loss, high level expression of transforming growth 
factor-beta (TGF-beta), high expression of DNA 
metiltransferase (DNMT1) mRNA are found in 
significant percentage of HCCs. 
There is increased risk of developing HCC in 
several rare inherited disorders: glycogen storage 
disease, alpha-1-antitrypsin deficiency, metal storage 
disease and chronic cholestatic syndromes [21].  
 
 
Diagnosis 
 
In many patients, HCC is asymptomatic and 
when symptoms occur they are usually related to 
those of chronic liver disease such as yellowing of the 
skin and eyes, pain in the right upper abdominal side, 
swelling of the abdomen, weakness, weight loss, fever 
[19, 22]. Over the past decades more asymptomatic 
patient are being diagnosed as a result of the active 
surveillance and the increased awareness of HCC in 
high risk patients, especially in those with cirrhosis. 
Screening for HCC in these patients is recommended 
every six months [1] and most used tools are serum 
levels of alpha-fetoprotein (AFP) and ultrasound [22]. 
Also the role of the serum level of AFP not always 
correlate with the tumor growth and it has been 
showed that is less useful than previously tough [23]. 
Review Article 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  734                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
Generally values over 400 ng/mL can confirm the 
diagnosis in 20% of HCC patients [19]. The diagnosis 
of HCC can be made by history, physical examination 
and using noninvasive imaging methods such as 
ultrasound, MRI and CT scan. Suspicious lesion in the 
liver detected by ultrasound usually requires additional 
imaging methods to confirm the diagnosis and to 
detect additional, smaller, lesions that previously were 
not seen. Specificity and sensitivity of the ultrasound 
depends on the size of the tumor, ability to detect 
tumors 3-5cm in diameter is 80-95% and 60-80% of 
tumors <1cm in diameter [5, 24]. Standard 
noninvasive diagnostic methods for diagnosing HCC 
are dynamic multiphasic multidetector-row CT 
(MDCT) and magnetic resonance imaging (MRI) [25]. 
Typical finding for HCC in contrast enhanced CT is 
arterial phase enhancement followed by loss of 
enhancement (washout) in the portal venous and 
delayed phases [26]. This image finding has a 
sensitivity of 90% and specificity of 95% for 
diagnosing HCC [26, 27]. Nodules less that 1 cm are 
difficult to assess and usually image-guided biopsy 
should be considered for these lesions [28]. This also 
should be done for focal hepatic masses with atypical 
imaging features or discrepant findings on CT and 
MRI, or for lesions detected in the absence of 
cirrhosis [1]. A negative result from the biopsy does 
not rule out malignancy and continuous surveillance 
and ultrasound check up is needed in intervals from 3 
till 6 months until they grow in size or change their 
echo pattern [29].  
 
 
Treatment 
 
Tumor staging has an essential role in guiding 
and making decision for further treatment. There are 
many systems to use in patients with HCC, but today 
most effective and most used is the Barcelona Clinic 
Liver Cancer (BCLC) classification [30] (Figure 3).  
 
Figure 3: Barcelona Clinic Liver Cancer (BCLC) classification. *PST 
– Performance Status Test 
 
Performance status scale is developed by the 
Eastern Cooperative Oncology Group (ECOG) is 
included in BCLC system and is used to evaluate the 
progression of diseases (Figure 4). 
 
________________________________________________________________________ 
Grade 
0. Fully active, able to carry on all pre-disease performance without restriction 
1. Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office work 
2. Ambulatory and capable of all self-care but unable to bed or chair more than 
50% of walking hours 
3. Capable of only limited self-care, confined to bed or chair more than 50% of 
walking hours 
4. Completely disabled. Cannot carry on any self-care. Totally confined to bed 
or chair 
5. Dead 
________________________________________________________________________ 
Figure 4: Performance status 
 
Child-Turcotte-Pugh score which is also 
included in BCLC is used to assess the prognosis of 
chronic liver disease (Figure 5). 
 
Figure 5: Child-Turcotte-Pugh score 
 
Using the BCLC system can help the doctor 
classify the patients with early-stage HCC, who may 
benefit from curative therapies and the patients with 
advanced-stage disease who would need palliative 
treatment. Sadly majority of patients present with 
advanced HCC at the time of diagnosis and are not 
candidate for curative therapies. Depending of the 
stage of the disease there are several therapeutic 
choices: surgical resection, percutaneous ethanol 
injection (PEI), radiofrequency ablation (RFA), 
transarterial chemoembolization (TACE) and radio-
embolization [31].  
First option for patients who have optimal 
profile according to BCLC staging system should be 
resection [32]. Surgical resection is the choice of 
treatment for patients with single nodules, no 
underlying cirrhosis and good liver function [33]. 
Treatment with PEI and RFA are optimal treatment 
option for patients with small tumours who are not 
candidates for surgical resection or liver 
transplantation [26]. Treatment with radiofrequency 
ablation demonstrated that complete ablation of 
lesions smaller than 2 cm is possible in more than 
90% of cases, with a local recurrence rate of less than 
1% [32, 34]. Survival rates after this treatment is 
100% at first year and 98% at second year [1]. 
Standard treatment for the patients with intermediate-
stage HCC is TACE. Patients with compensated liver 
function (Child B up to 8 points), with large single 
nodule (< 5 cm) or multifocal HCC without evidence of 
vascular invasion or extra hepatic spread are 
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considered candidates for TACE [33]. Also TACE 
plays an important role in the palliative treatment and 
it is a standard choice of treatment in patients with 
asymptomatic multinodular disease [35]. The 
prognosis of patients with HCC is poor in symptomatic 
patients in whom five-year survival rate is reported to 
be less than 5%. It is very poor in patients with AFP 
levels greater than 100ng/ml at the time of diagnosis, 
portal vein thrombosis and presence of p53 mutation. 
Long –term survival is reported only in patients with 
small, asymptomatic HCC (Table 1). 
Table 1: Estimated Incidence, Mortality and Prevalence of liver 
cancer Worldwide in 2012. Estimated numbers (thousands) 
http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp 
 
Men Women Both sexes 
Cases Deaths 
5-year 
prev. 
Cases Deaths 
5-year 
prev. 
Cases Deaths 
5-year 
prev. 
 World 554 521 453 228 224 180 782 746 633 
 More developed 
regions 
92 80 112 42 43 51 134 123 164 
 Less developed 
regions 
462 441 341 186 182 129 648 622 469 
 WHO Africa region 
(AFRO) 
25 24 17 14 13 9 39 37 26 
 WHO Americas 
region (PAHO) 
40 35 35 23 23 18 63 58 53 
 WHO East 
Mediterranean 
region (EMRO) 
20 19 12 10 9 6 29 28 18 
 WHO Europe 
region (EURO) 
47 44 42 23 25 20 71 69 61 
 WHO South-East 
Asia region 
(SEARO) 
55 52 33 25 24 15 80 77 48 
 WHO Western 
Pacific region 
(WPRO) 
368 347 314 133 129 112 501 477 426 
 IARC membership 
(24 countries) 
120 104 135 56 55 60 176 159 195 
 United States of 
America 
23 17 21 8 7 7 30 24 27 
 China 293 282 220 101 101 71 395 383 291 
 India 17 17 8 10 10 5 27 27 13 
 European Union 
(EU-28) 
36 32 33 16 17 14 52 48 47 
 
The development of new drugs and types of 
therapy can improve the outcome of patients with 
hepatocellular carcinoma, but the key factor in 
management of HCC is still making a diagnosis in the 
very-early stages of disease and continuously 
surveillance of the patients with a high risk of HCC [1, 
36, 37].  
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